Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 3,190,000 | 3,076,400 | 2,964,700 | 2,770,200 | 2,911,999 |
| Cost of Goods | 466,000 | 414,800 | 407,500 | 363,000 | 423,400 |
| Gross Profit | 2,724,000 | 2,661,600 | 2,557,200 | 2,407,200 | 2,488,600 |
| Operating Expenses | 1,518,100 | 1,476,200 | 1,406,600 | 1,777,100 | 1,463,001 |
| Operating Income | 1,205,900 | 1,186,200 | 1,151,100 | 630,100 | 1,026,000 |
| Interest Expense | 3,300 | 3,300 | 3,700 | 3,000 | 2,800 |
| Other Income | 128,400 | 115,900 | 135,600 | 103,300 | 113,300 |
| Pre-tax Income | 1,331,000 | 1,298,800 | 1,283,000 | 730,400 | 1,136,500 |
| Income Tax | 139,900 | 215,900 | 250,100 | 84,100 | 223,500 |
| Net Income Continuous | 1,191,100 | 1,082,900 | 1,032,900 | 646,300 | 913,000 |
| Net Income | $1,191,100 | $1,082,900 | $1,032,900 | $646,300 | $913,000 |
| EPS Basic Total Ops | 4.68 | 4.24 | 4.02 | 2.52 | 3.53 |
| EPS Basic Continuous Ops | 4.68 | 4.24 | 4.02 | 2.52 | 3.54 |
| EPS Diluted Total Ops | 4.64 | 4.20 | 3.99 | 2.49 | 3.62 |
| EPS Diluted Continuous Ops | 4.64 | 4.20 | 3.99 | 2.49 | 3.63 |
| EPS Diluted Before Non-Recurring Items | 4.65 | 4.22 | 4.00 | 3.55 | 3.54 |
| EBITDA(a) | $1,261,601 | $1,240,200 | $1,202,800 | $678,500 | $1,072,498 |